Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
Emil ter Veer, L. Bengt van Rijssen, Marc G. Besselink, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. e151-e160
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review
Ross D. Dolan, Barry Laird, Paul G. Horgan, et al.
Critical Reviews in Oncology/Hematology (2018) Vol. 132, pp. 130-137
Open Access | Times Cited: 122
Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
Michael S. Yule, Joshua A. Thompson, Khachonphat Leesahatsawat, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 3, pp. 853-867
Open Access | Times Cited: 11
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study
Julius Keyl, Andreas Bucher, Friederike Jungmann, et al.
ESMO Open (2024) Vol. 9, Iss. 1, pp. 102219-102219
Open Access | Times Cited: 6
The Use of (Network) Meta-Analysis in Clinical Oncology
Emil ter Veer, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 52
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment
Qiaofei Liu, Huanwen Wu, Yuan Li, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 8, pp. 1477-1492
Open Access | Times Cited: 46
The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients
Allan M. Golder, Donald C. McMillan, James H. Park, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 11, pp. 1828-1835
Open Access | Times Cited: 28
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
Tsuyoshi Shirakawa, M. Shimokawa, Taiga Otsuka, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 8, pp. 100150-100150
Closed Access
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010928-e010928
Open Access
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Li‐Tzong Chen, Teresa Macarulla, Jean–Frédéric Blanc, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1068-1068
Open Access | Times Cited: 27
The association between wearable activity monitor metrics and performance status in oncology: a systematic review
Milan Kos, Esther N. Pijnappel, Laurien M. Buffart, et al.
Supportive Care in Cancer (2021) Vol. 29, Iss. 11, pp. 7085-7099
Open Access | Times Cited: 21
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Héctor van den Boorn, Ameen Abu‐Hanna, Emil ter Veer, et al.
Cancers (2019) Vol. 11, Iss. 2, pp. 187-187
Open Access | Times Cited: 23
Prognostic impact of Charlson’s Age‐Comorbidity Index and other risk factors in patients with pancreatic cancer
Karin Bagni, Inna M. Chen, Astrid Z. Johansen, et al.
European Journal of Cancer Care (2020) Vol. 29, Iss. 3
Open Access | Times Cited: 23
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
Taiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology (2021) Vol. 26, Iss. 5, pp. 941-950
Closed Access | Times Cited: 19
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)
Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
Journal of Geriatric Oncology (2021) Vol. 13, Iss. 1, pp. 82-87
Closed Access | Times Cited: 18
Radiomics Facilitates Candidate Selection for Irradiation Stents Among Patients With Unresectable Pancreatic Cancer
Hai-Feng Zhou, Yuqi Han, Jian Lü, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 21
The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies
Pedro Luiz Serrano Usón, Fernanda Davila Sampaio Tolentino, Vanessa Montes Santos, et al.
PLoS ONE (2020) Vol. 15, Iss. 3, pp. e0230060-e0230060
Open Access | Times Cited: 20
Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis
Tara M. Mackay, Anouk E.J. Latenstein, Mirjam A. G. Sprangers, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 10, pp. 1354-1363
Open Access | Times Cited: 20
Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
Yongchun Song, Xiuli Chen, Xuyao Yu, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma
Paul McLellan, Julie Henriques, Feryel Letaief Ksontini, et al.
Clinics and Research in Hepatology and Gastroenterology (2020) Vol. 45, Iss. 3, pp. 101541-101541
Open Access | Times Cited: 17
Systemic Inflammation and Outcome in 2295 Patients with Stage I–III Colorectal Cancer from Scotland and Norway: First Results from the ScotScan Colorectal Cancer Group
James H. Park, Anniken Jørlo Fuglestad, Anne Helene Køstner, et al.
Annals of Surgical Oncology (2020) Vol. 27, Iss. 8, pp. 2784-2794
Open Access | Times Cited: 15
A Low Total Psoas Muscle Area Index Is a Strong Prognostic Factor in Metastatic Pancreatic Cancer
Nicolas Williet, Marion Fovet, Khawla Maoui, et al.
Pancreas (2021) Vol. 50, Iss. 4, pp. 579-586
Closed Access | Times Cited: 13
FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world
Norbert Marschner, Susanna Hegewisch‐Becker, Marcel Reiser, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 3, pp. 458-469
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top